J&J Data Support Earlier Use of Combo Pill in Prostate Cancer

J&J data support earlier use of combo pill in prostate cancer

According to J&J, Akeega is the first PARP inhibitor combination that’s proven effective treating earlier-stage prostate tumors that harbor mutations in genes beyond BRCA.

ASCO 2025: Johnson & Johnson’s Akeega set to be first PARP therapy for mCSPC

Global Akeega sales will reach $676 million by 2030, while Talzenna and saruparib reach $618 million and $628 million respectively.The post ASCO 2025: Johnson & Johnson’s Akeega set to be first PARP therapy for mCSPC appeared first on Clinical Trials Arena.

PARP-ARPI Combo Sets New Standard for Metastatic Hormone-Sensitive Prostate Cancer

(MedPage Today) — CHICAGO — Men with homologous recombination repair (HRR)-deficient, metastatic, castration-sensitive prostate cancer (mCSPC) lived significantly longer without disease progression when they received a PARP inhibitor in addition… Source link : https://www.medpagetoday.com/meetingcoverage/asco/115861 Author : Publish date : 2025-06-03 12:00:00 Copyright for syndicated content belongs to the linked Source. The post PARP-ARPI Combo…

Johnson & Johnson leads with first PARP inhibitor combo to improve efficacy in patients with HRR-altered mCSPC

Results from the Phase 3 AMPLITUDE study show the potential of AKEEGA® (niraparib and abiraterone acetate dual-action tablet) to delay cancer progression and worsening of symptoms